The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure - Tabular View

Tracking Information

First Received Date ^ICMJE

August 18, 2005

Last Updated Date

August 30, 2007

Start Date ^ICMJE

August 2005

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

change in glucose uptake

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00132106 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

The Effect of Alfa-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure

Official Title ^ICMJE

The Effect of a-Adrenergic Receptor Blockade on Insulin-Stimulated Forearm Glucose Uptake and Metabolism in Chronic Heart Failure

Brief Summary

The activity of the sympathetic nervous system seems to influence the uptake (and handling) of glucose by the skeletal muscle of the forearm. Conditions in which sympathetic activity is increased seem to inhibit/reduce forearm glucose uptake. Inversely a decrease in sympathetic activity seems to increase glucose uptake. This study analyzes the effect of alfa-adrenergic receptor blockade (counteracting sympathetic influence) on insulin-stimulated forearm glucose uptake in patients with increased sympathetic activity (patients with chronic heart failure).

Detailed Description

Study Phase

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Non-Randomized, Open Label, Active Control, Single Group Assignment

Condition ^ICMJE

Heart Failure, Congestive

Intervention ^ICMJE

Drug: phentolamine

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Heart failure of at least New York Heart Association (NYHA) class II
Left ventricular ejection fraction (LVEF) <= 40%
Age 18-75 years

Exclusion Criteria:

Alfa-blockers, or beta-blockers with alfa-blocking activity (carvedilol)
Tricyclic antidepressants
Warfarin derivatives (acetylic salicylic acid and clopidogrel are allowed)
Hospitalisation in 6 weeks prior to the study
Any change in medication in 6 weeks prior to the study
Unstable angina
Orthopnoea
Known chronic disease of the autonomic nervous system
Diabetes mellitus
Oedema of the lower extremities, complicating the insertion of a venous catheter in a vein on the foot

Gender

Both

Ages

18 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Marc E.R. Gomes, MD

+31-24-3614533/3616550

m.gomes@cardio.umcn.nl

Location Countries ^ICMJE

Netherlands

Administrative Information

NCT ID ^ICMJE

NCT00132106

Responsible Party

Study ID Numbers ^ICMJE

CHFALFA

Study Sponsor ^ICMJE

Radboud University

Collaborators ^ICMJE

ZonMw: The Netherlands Organisation for Health Research and Development

Investigators ^ICMJE

Principal Investigator:

Cees J Tack, MD, PhD

Radboud University

Information Provided By

Radboud University

Verification Date

August 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP